Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pfizer to seek to expand COVID-19 vaccine EUA to children aged 5 to 11

By Brian Buntz | July 2, 2021

Pfizer BioNTechPfizer (NYSE:PFE) and its partner BioNTech (NSDQ:BNTX) aim to expand the U.S. emergency use authorization (EUA) for their COVID-19 vaccine to include children aged five to 11.  

The companies plan on filing paperwork for the expanded EUA over the coming months. “We are planning for emergency use authorization submission for [children aged five to 11] in September or October of this year, and the [two-to-five-year-old] group to follow soon thereafter,” Alejandra Gurtman, MD, Pfizer’s vice president of vaccine clinical research and development, said during a virtual symposium.

FDA has already authorized the vaccine for people 12 and older. 

Pfizer’s Phase 1/2/3 study testing vaccine safety and efficacy in children has enrolled approximately 4,500 participants aged six months to 11 years old. Some 90 clinical trial sites in the U.S., Poland, Spain and Finland are taking part in the trial. 

The Phase 1/2/3 trial involving children aged six months to 11 years old has sorted participants into three groups. Children in the first group are five to 11 years old. The second consists of children two to five years old. In the final group are children who are six months to two years old. 

As with adult study participants in earlier trials, the children in the study are receiving two doses administered 21 days apart.

Clinical trial investigators decided to test 3-µg levels in children aged six months to two years and the two-to-five-year-old group. Those aged five to 11 are receiving the 10-µg doses of the vaccine 

To infer efficacy, Pfizer is comparing the results from the trial with those from clinical trial participants who are 16 to 25 years of age. 

The study is randomizing participants using a 2:1 ratio with the greater amount receiving the BNT162b2 vaccine. 


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: BioNTech, BNT162b2, coronavirus, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, emergency use authorization, EUA, Pfizer, Pfizer Inc.
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

JYNNEOS vaccine
Jynneos vaccine: The best weapon against monkeypox?
Axcella
Axcella touts positive results from Phase 2a long COVID study
monkeypox
3 critical monkeypox vaccine questions 
Moderna in the Drug Discovery & Development Pharma 50
Moderna inks deal with US for up to 300M omicron boosters

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50